Malignant gliomas are the most common and fatal
brain tumors in adults. In particular, the strong invasiveness of
glioma cells into the normal brain tissue makes eradication of
glioma very difficult.
Matrix metalloproteinases (
MMPs) play a pivotal role in
glioma invasion, and thus controlling
MMP expression has been suggested as an important therapeutic target for
brain tumors. In the present study, we investigated the effect of
protopanaxatriol ginsenoside Rh1 on
MMP expressions in human
astroglioma U87MG and U373MG cells. RT-PCR analysis showed that Rh1 inhibits the
mRNA expressions of MMP-1, -3, and -9 in PMA-stimulated U87MG and U373MG cells. Rh1 also suppressed the promoter activities of MMP-1, -3 and -9. The ELISA, Western blot, and zymographic analyses revealed that Rh1 inhibits the
protein expression and/or enzymatic activity of MMP-1, -3 and -9. In accordance with the strong inhibitory effects of Rh1 on
MMPs, Rh1 efficiently inhibited the invasion and migration of U87MG and U373MG
glioma cells as demonstrated by
Matrigel invasion assay and wound healing assay. Further mechanistic studies revealed that Rh1 inhibits MAPK and PI3K/Akt signaling pathways and downstream
transcription factors such as NF-κB and
AP-1, which play an important role in
MMP gene expressions. The data collectively suggest that
ginsenoside Rh1 may have a therapeutic potential for
malignant gliomas.